The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
Open accessAbstract
Protease inhibitors are potent antiviral agents against human immunodeficiency virus type 1. As with reverse transcriptase inhibitors, however, resistance to protease inhibitors can develop and is attributed to the appearance of mutations in the protease gene. With the substrate analog protease inhibitors BILA 1906 BS and BILA 2185 BS, 350- to 1,500-fold-resistant variants have been selected in vitro and were found not only to contain mutations in the protease gene but also to contain mutations in Gag precursor p1/p6 and/or NC (p7)/p1 cleavage sites. Mutations in cleavage sites give rise to better peptide substrates for the protease in vitro and to improved processing of p15 precursors in drug-resistant clones. Importantly, removal of cleavage site mutations in resistant clones leads to a decrease or even an absence of viral growth, confirming their role in viral fitness. Therefore, these second-locus mutations indicate that cleavage of p15 is a rate-limiting step in polyprotein processing in highly resistant viruses. The functional constraint of p15 processing also suggests that additional selective pressure could further compromise viral fitness and maintain the benefits of antiviral therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Characterization of ribosomal frameshifting in HIV-1 gag-pol expression
Jacks, T., Power, M. D., Masiarz, F. R., Luciw, P. A., Barr, P. J., & Varmus, H. E. (1988) · Nature · doi:10.1038/331280a0 · Cited by 966
Cited by
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance
Wainberg, M. A. (1998) · JAMA · doi:10.1001/jama.279.24.1977 · Cited by 498
Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1
Martinez-Picado, J., Savara, A. V., Sutton, L., & D’Aquila, R. T. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3744-3752.1999 · Cited by 396
Zhang, Y. M., Imamichi, H., Imamichi, T., Lane, H. C., Falloon, J., Vasudevachari, M. B., & Salzman, N. P. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.6662-6670.1997 · Cited by 320
Metadata
- Authors
- Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., & Lamarre, D.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 1996-06
- Volume
- 70
- Issue
- 6
- Pages
- 3763-3769
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W1595757174
- Cited by
- 295
- References
- 1
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. https://app.cochat.ai/papers/10.1128/jvi.70.6.3763-3769.1996
- The paper
- Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., & Lamarre, D. (1996). Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. Journal of Virology. https://doi.org/10.1128/jvi.70.6.3763-3769.1996
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.